Budgetary Impact Analysis of Alteplase - Recombinant Tissue Plasminogen Activator (RTPA) - As a Thrombolytic Treatment for Acute Ischemic Stroke in Colombia
Author(s)
Lasalvia P
NeuroEconomix, BOGOTA, CUN, Colombia
Presentation Documents
Objectives: to evaluate the potential impact on costs and health outcomes of increasing the proportion of patients with acute ischemic stroke (AIS) who are thrombolyzed with alteplase in Colombia and of reducing the time to initiate treatment. Methods: We developed a budget impact modal estimating with a 5-year time horizon from the perspective of the third-party payer in Colombia. We obtained epidemiological data from local sources and published studies. We established healthcare resource utilization with base case with local clinical experts and costing was performed with local tariff manuels. Efficacy data was extracted from published literature. We considered three windows for treatment initiation: 0-90, 91-180, and 181-270 minutes. Costs were expressed in US dollars of 2020. (2020, 1 USD = $3,693.36 COP) Results: The increase in thrombolyzed patients from 10 to 22% would decrease the number of patients with sequelae by 1,721, 2,594 and 1,007 in the ranges of 0-90 minutes, 91-180 and 181-270, respectively. The budget effort required for each of the treatment initiation ranges is of USD$15,525,649(5.5%), USD$16,665,304(5.7%) and USD$16,963,231(7.0%), respectively. Conclusions: From the perspective evaluated, doubling the number of patients with AIS who are thrombolyzed would lead to reductions in the number of patients with sequelae and would require a budgetary effort of 5.5-7.0%. The early initiation of treatment (0-180minutes) gives an additional benefit in reducing the number of sequelae and a lower budgetary impact than initiation within the last time window (181-270minutes).
Conference/Value in Health Info
2022-05, ISPOR 2022, Washington, DC, USA
Value in Health, Volume 25, Issue 6, S1 (June 2022)
Code
EE477
Topic
Economic Evaluation
Topic Subcategory
Budget Impact Analysis
Disease
Cardiovascular Disorders